Phase 3
Completed N=29
Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy
Source: ClinicalTrials.gov NCT00182000 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Yale-Brown Obsessive Compulsive Scale (YBOCS) — 10.2; 14.5 units on a scale
Summary
This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Yale-Brown Obsessive Compulsive Scale (YBOCS) |
10.2; 14.5 | — |
| SECONDARY Clinical Global Impressions Scale (CGI) |
— | — |
| SECONDARY Beck Depression Inventory (BDI) |
— | — |
| SECONDARY Beck Anxiety Inventory (BAI) |
— | — |
| SECONDARY Obsessional Beliefs Questionnaire (OBQ) |
— | — |
| SECONDARY Short-Form Health Survey (SF-36) |
— | — |
| SECONDARY Disability Inventory |
— | — |
Eligibility Criteria
Inclusion Criteria
- Structured Clinical Interview for DSM-IV (SCID) diagnosis of Obsessive Compulsive Disorder
- Score of greater than 16 on the Yale-Brown Obsessive Compulsive Scale
- Negative urinary beta-Human Chorionic Gonadotropin (hCG) test
Exclusion Criteria
- Currently taking or have taken an unstable dose of psychotropic medications within 2 months prior to enrollment
- Currently taking medications that may interfere with the study medication
- History of seizure disorder or other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood-related disease)
- Current diagnosis of tuberculosis
- Other psychiatric diagnoses (e.g., alcohol dependence, bipolar disorder, psychosis, organic mental disorder, or development disorder) that are of greater concern than the obsessive-compulsive disorder diagnosis
- Currently taking medications that may lower seizure threshold (e.g., including clozapine, pethidine, and the following antibiotics in high dosage: penicillins, cephalosporins, amphotericin, and imipenem)
- Poses a serious suicidal or homicidal threat
- Currently undergoing psychotherapy
- Failure to benefit from ten or more sessions of previous Exposure and Response Prevention (ERP) treatment
- Pregnant or breastfeeding
Data sourced from ClinicalTrials.gov (NCT00182000). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.